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Abstract 
Background: Many self-management programs have been developed so far. Their effectiveness varies. The program 
‘Beyond Good Intentions’ (BGI) is based on proactive coping and has proven to be (cost-) effective in achieving reduc-
tions in BMI and blood pressure in screen-detected type 2 diabetes patients up until nine months follow-up. However, 
its long-term effectiveness in people already known with diabetes is lacking. In addition, its (cost-) effectiveness might 
increase if people who are likely not to be benefit from the program are excluded in a valid way. Therefore it was 
aimed to investigate the long-term effects of the educational program BGI on cardiovascular risk, quality of life and 
diabetes self-management behaviour in a pre-selected group of patients known with type 2 diabetes up to 5 years.
Methods: Randomised controlled trial with 2.5 year follow-up. Adults (≤75 years) with a type 2 diabetes duration 
between 3 months and 5 years will be included. With the use of a self-management screening tool (SeMaS) their 
potential barriers of self-management due to depression and/or anxiety will be determined. Based on the results 
of the SeMaS selection patients will be randomised (1:1) to the BGI-group (n = 53) or the control-group (n = 53). In 
addition to receiving usual care, patients in the BGI-group will follow the 12-week theory-based self-management 
program and a booster session a few months thereafter. The control-group will receive care as usual. The primary 
outcome is change in Body Mass Index after 2.5 years follow-up. Secondary outcomes are HbA1c, lipid profile and sys-
tolic blood pressure, (diabetes) quality of life, level of physical activity, dietary intake and medication adherence and 
proactive coping. Cost-effectiveness will be based on total use of health care resources during the entire study period. 
Difference between groups in change over time will be analysed according to intention-to-treat analysis.
Conclusions: By differentiating between patients who will and those who are likely not to benefit from the educa-
tional program, a more (cost-) effective self-management program might be designed, also on the long-run.
Trial registration NTR 5330
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Background
Diabetes self-management forms a major part of diabe-
tes treatment and involves several complex behaviours, 
such as adhering to a treatment regimen, monitoring 
symptoms, maintaining a healthy lifestyle and managing 
the impact of the disease on one’s life. People with type 
2 diabetes mellitus (T2DM) are expected to take more 
and more responsibility in this, but for many of them self-
management is difficult to incorporate in daily life and not 
all patients will possess the necessary skills for this. The 
motivation to initiate changes in behaviour is often pre-
sent, but patients do not know what needs to change or 
maintain the achieved behavioural lifestyle when barriers 
are encountered. We developed the Beyond Good Inten-
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act upon their intentions. It is based on the theories of 
self-regulation and proactive coping [1], assuming that 
people should control and direct their actions in order to 
meet their goals. Pro-active coping refers to efforts under-
taken in advance of a potentially stressful event to prevent 
or modify its form before it occurs [1]. BGI has proven to 
be effective in patients with screen-detected T2DM up 
until 9 months follow-up [2]. Based on a computer-based 
simulation model to project long-term health benefits 
and cost-effectiveness, BGI was among the four diabetes 
self-management programs worldwide, with a minimum 
follow-up of 12  months, with the best cost-effectiveness 
ratio [3]. However, real, not modelled, long-term data on 
(cost-) effectiveness of BGI are lacking and also its effec-
tiveness in people who are known with T2DM and not 
screen-detected, is unclear.
Group based educational programs for diabetes self-
management can improve blood glucose, blood pressure, 
body mass index (BMI) and the requirement of blood glu-
cose lowering drugs; however, the long-term results were 
varying [4]. In Italy, non-insulin-treated T2DM patients 
known with diabetes for at least 1 year were randomised 
to either group or individual care in a hospital-based set-
ting. After 4  years clinical, cognitive, and psychological 
outcomes were better in the group based treatment [5]. 
In the DESMOND trial, greater improvements in weight 
loss and smoking cessation were found in the interven-
tion group at 1-year-follow-up, but at 3-year-follow-
up this effect was no longer apparent [6, 7]. In general, 
completers of a diabetes self-management intervention 
study are significantly more highly educated than drop-
outs [8]. This indicates that interventions to improve 
self-management should be tailored to different catego-
ries of patients. The ‘one size fits all’ principle in diabe-
tes education research is outdated. To estimate a priori 
the chance of successful self-management of a patient, 
the self-management screening tool (SeMaS) can be used 
[9]. With SeMaS possible barriers for self-management 
due to depression and/or anxiety can be detected. Both 
depression and anxiety can interfere with the effective-
ness of a self-management program at that moment for a 
particular person and should be dealt with before follow-
ing the program. Besides, individuals with already high 
self-management capabilities are likely to have no addi-
tional benefit from an educational course [10–12].
We hypothesise that by differentiating between 
patients who may and those who may not benefit from 
a self-management program, a more (cost-) effective self-
management education program can be designed which 
is also effective on the long-run. Therefore, the aim of 
the current study is to investigate the cost-effectiveness 
and long-term effects of the educational program BGI 
on cardiovascular risk, quality of life and diabetes self-




In Dutch primary care, most patients (80–85%) are 
treated within disease management programs, contracted 
by so called care groups. These care groups are respon-
sible for the organisation, coordination and delivery of 
diabetes care in primary care [13, 14]. Three care groups 
with 43 general practices (both group and single handed 
practices, with 89 general practitioners) in the southern 
part of the Netherlands participate in the current study.
Study design and selection criteria
The study is designed as a parallel randomised controlled 
trial with 2.5  years follow-up and will follow the CON-
SORT criteria for experimental designs [15]. Along with 
the BGI self-management education program (obviously 
only for the intervention group) all participants will 
receive diabetes care according to the guidelines of the 
Dutch College of General practitioners [16].
Inclusion criteria
  – Adults, aged ≤75 years.
  – Diagnosed with T2DM between 3 months–5 years ago.
Exclusion criteria
  – High self-management capability on all SeMaS 
domains (see below).
  – High scores on the SeMaS domains ‘Anxiety’ or 
‘Depression’ (see below).
  – Insufficient cognitive functioning.
  – Insufficient understanding of the Dutch language to 
follow instructions and to complete questionnaires.
Ethical approval
The study was approved by the Medical Ethical commit-
tee of the University Medical Centre Utrecht and reg-
istered at the Dutch Trial Register (Netherlands Trial 
Register NTR5330).
Recruitment
The electronic medical records from the people with 
T2DM from the participating general practitioners are 
scrutinised to find eligible T2DM patients. All patients 
who meet the inclusion criteria will be informed about 
the possibility to follow a group-based diabetes self-
management education program with pre-selection 
(see further), emphasising that they will be only offered 
an educational program they are likely to benefit from. 
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People can indicate on a response card whether or not 
they want to receive oral information about the study. If 
yes, a research team member will give the patient a tel-
ephone call to discuss the study. If the patient is informed 
and understands the information, informed consent will 
be completed. Once the patient has given informed con-
sent the pre-selection will take place.
Pre‑selection
The pre-selection procedure to assess a patient’s capabili-
ties of self-management will be performed with the use 
of the SeMaS, a self-management screening tool which 
is validated in T2DM patients and sent to the patients 
home [9]. The SeMaS is a 27 item questionnaire covering 
self-management abilities of five psychosocial domains 
[locus-of-control (3 items), self-efficacy (2 items), social 
support (1 items), coping (9 items), anxiety (4 items) and 
depression (3 items)], three skills items (computer, group 
and self-care) and two other items including perceived 
burden of disease [9]. All separate items range from 0 to 
3 on a 4-point Likert scale (locus-of-control, self-efficacy, 
coping, skills items) or from 0 to 2 on a 3-point Likert 
scale (social support, anxiety, depression). For all items 
higher scores represent higher capability, except for those 
in the anxiety and depression domain where higher score 
represent more barriers. The perceived burden of disease 
is scored on a visual analogue scale from 0 to 10. Patients 
with high scores on the domains anxiety (score >4 from 
total 8) and/or depression (score  >3 of total 6) will be 
excluded during the pre-selection. Those patients first 
need to deal with their mood disturbance before they are 
able to improve their self-management skills. Patients 
without barriers for self-management, so with maximal 
self-management capacity (highest possible scores for the 
locus-of-control, self-efficacy, social support, coping and 
for anxiety ≤4 and for depression ≤3) were also excluded, 
since they would not benefit from the educational course. 
The general practitioner (GP) will be informed about the 
SeMaS scores of all participants.
Randomisation
Patients who are eligible after the pre-selection will be 
randomised (1:1) based on computer-generated ran-
dom numbers, with sealed, opaque, sequentially num-
bered allocation envelopes. All patients entering the trial 
receive a random number from the coordinating research 
centre (Julius Center). Each number corresponds to 
either ‘BGI course’ (BGI-group) or ‘no BGI course’ (con-
trol-group). As patients will attend a course in the inter-
vention group, it is not possible to blind participants for 
the treatment allocation. Patients from the same prac-
tices and general practitioners will attend a different 
course, so no large cluster-effect is expected.
Intervention: beyond good intentions (BGI)
This study elaborates on the existing self-management 
program BGI [2, 17, 18]. It lasts 12 weeks and consists of 
one initiating 30-min individual session and four 2.5-h 
group sessions. In addition, one booster-session is given a 
few months after the last group session. The course struc-
ture is as follows:
Individual session
The patient’s knowledge, attitudes and ambivalence with 
regard to diabetes management will be discussed. For this 
purpose the ‘Diabetes Profile’ was specifically designed to 
help patients gaining insight in the risk factors associated 
with their diabetes. With a colour scheme, from green to 
red, their risk for long-term complications is presented. 
Patients are encouraged to set goals to work on. The 
trained practice nurse (see further) discusses glycaemic 
control, BMI, blood pressure and lipids profile with the 
patient. Patients are asked to formulate a first goal before 
the first group session and will receive the educational 
material that will be discussed during the group sessions.
Group sessions
The group sessions are held in groups of six to ten partic-
ipants and take place every two to three weeks in a loca-
tion nearby the patients’ homes. The first three sessions 
will cover topics that are relevant for all patients: physi-
cal activity, healthy diet and medication adherence (what 
do guidelines tell, why it is important to follow these 
guidelines and how to do it, what are known barriers in 
this respect, what might facilitate compliance, followed 
by individual goals to improve). In the fourth session 
patients will be able to work on a personally relevant goal.
Every group session starts with the introduction of the 
topic, patients are asked to share their opinions, emo-
tions and experiences regarding the topic. Subsequently, 
patients write their own individual action plan, according 
to the proactive coping five-step plan:
 – Step 1: Formulate a concrete and attainable goal.
  – Step 2: What are necessary conditions and possible 
barriers?
  – Step 3: What may be alternative strategies for crossing 
these possible barriers?
  – Step 4: Formulate the final plan: what, how, where, and 
when?
 – Step 5: Indicate how the progress will be evaluated and 
when you are satisfied, the plan is discussed with the 
group to improve the final plan.
During the weeks in between the groups sessions 
patients will practice with their individual action plane, 
which will be evaluated during the next meeting.
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In case of diabetes-related questions, patients are 
encouraged to collect additional information by them-
selves, e.g. on the Internet or by referring them to 
another professional like a physiotherapist or dietician. 
This way, patients are encouraged to take responsibility 
for their disease.
Booster session (evaluation)
In this session the past months will be discussed and 
goals will be evaluated. New goals will be set. In addition, 
the trainers will motivate the participants to bring up a 
topic for the booster.
Nurse training
The BGI course will be given by trained practice nurses 
(n  =  3). They receive two 3-h training sessions from 
the psychologist who is familiar with the BGI training 
(Train-the-trainer principle). During the training they 
will work with the five-step proactive coping plan and 
will be taught on the principles of the self-regulation and 
pro-active coping theory. The practice nurse should have 
the role of facilitator and coach, stimulating participants 
to support each other and become self-confident in seek-
ing information.
Control group
As stated above, participants in the control group will 
receive similar diabetes care as those in the interven-
tion group, according to the guidelines of the Dutch Col-
lege of General Practitioners [16]. The only difference 
between both groups will be the additional BGI course.
Outcome measures
Primary outcome measure
The primary outcome measure will be the same as in the 
original BGI study for comparison reasons and is there-
fore; change in BMI (difference of 0.77 kg/m2 is consid-
ered clinical relevant) between baseline and follow-up 
(2.5 years after the start of the BGI program).
Secondary outcome measures
The secondary outcomes will be change between baseline 
and 2.5 years follow-up of:
1. Clinical measures: systolic blood pressure, HbA1c, 
lipid profile (total cholesterol, LDL, HDL, triglycer-
ides);
2. Diabetes self-management behaviour (self-care, 
physical activity, dietary intake, medication adher-
ence);
3. Proactive coping;
4. Quality of Life;
5. Cost-effectiveness of the intervention (total health 
care resources use during the entire study period).
Measurements
Clinical measures
In both groups, BMI, systolic blood pressure, HbA1c and 
lipid profiles will collected from the electronic medical 
record at baseline and 2.5 years follow-up. Clinical meas-
ures in-between will also be extracted from the electronic 
medical record of the GP.
Questionnaires
Participants will be asked to complete questionnaires to 
measure diabetes self-management behaviour, proactive 
coping and quality of life at baseline and 2.5 years follow-
up, with the following measures.
Diabetes self‑management behaviour
(a) The SDSCA, revised according to Toobert et al. [19], 
includes eleven items assessing several aspects of the 
diabetes regimen: general diet, specific diet, exercise, 
blood glucose testing, foot care, and smoking. Ten 
items are rated on an 8-point Likert scale, measur-
ing how many days an activity is performed in the 
last week. One item measures smoking status (yes/
no) and the amount of cigarettes smoked in the last 
week. Each of the domains is measured separately.
(b) The PASE questionnaire [20] includes 15 items, 
which cover leisure time physical activities (six 
items), household physical activities (six items), and 
work related physical activities (three items). Items 
differ in scoring range and are translated to the time 
spent on each activity into a composite score which 
reflects the amount of energy expended.
(c) The ‘Kristal food habits questionnaire’ [21] consists 
of 22 items assessing patient’s habits with regard to 
fatty food intake, dietary products and fruit and veg-
etable intake. The items differ in scoring ranges.
(d) The MARS-5 [22], is a brief 5-item instrument which 
assesses the degree to which patients forget medica-
tion, stop taking their medication or change dosages. 
Items range from 1 (always–never adherent) to 5 
(never–always adherent).
Proactive coping
Proactive coping will be measured with the ‘Proactive 
Diabetes Management Inventory’ (PDMI) [17], designed 
to evaluate the success of our course in getting patients 
to implement the five-step plan in their self-care. The 
instrument includes 7 statements covering different 
aspects of the five-step plan. The first six items assess 
whether patients think about their goals beforehand in 
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a proactive fashion; that is, do they anticipate the condi-
tions needed to reach their goal and do they anticipate 
barriers they may encounter along the way? Items 7–12 
assess whether patients anticipate and plan the strategies 
needed to achieve their goal. Finally, Items 13–17 assess 
whether patients monitor their progress and strategies 
and adapt these accordingly. The items range from 1 (def-
initely not) to 5 (definitely) [17].
Quality of life
The EuroQol EQ-5D, Short-Form 36 (SF36) and a dia-
betes-specific quality of life questionnaire, namely the 
Audit of Diabetes-Dependent Quality of Life (ADDQol) 
will be used to measure health-related quality of life as 
well as health status.
(a) The EQ 5D is a generic quality of life questionnaire, 
consisting of a Visual Analogue Scale (EQ  5D-VAS) 
and a classification system (EQ 5D-Profile) [23]. The 
EQ 5D-Profile covers five domains: mobility, self-care, 
usual activities, pain/discomfort and anxiety/depres-
sion of health, each with three levels of functioning: 
level 1, no problems; level 2, some problems; level 
3, severe problems. The EQ-5D health utility scores 
range from −0.33 to +1.00 and were computed using 
the Dutch tariff as described by Lamers et al. [24, 25]. 
A score of 0 is equal to death, whereas 1 indicates full 
health. Negative values represent a health state worse 
than death. The EQ  5D-VAS is a graduated, vertical 
line, anchored at 0 (worst imaginable health state) 
and 100 (best imaginable health state). The patient is 
asked to mark a point on the EQ  5D-VAS that best 
reflects his/her actual health state.
(b) The SF-36 generates a profile of scores on eight 
dimensions of health status: Physical Functioning (10 
items), Role Physical (4 items), Bodily Pain (2 items), 
General Health (5 items), Vitality (4 items), Social 
Functioning (2 items), Role-Emotional (3 items) and 
Mental Health (5 items). These scales can be summa-
rised in Physical Health and Mental Health. The 36 
items differ in the scoring ranges [26].
(c) The ADDQoL, measures the perceived impact of dia-
betes on the quality of life; it includes 19 items, rang-
ing from −3 to 3 on different questions, with 0 as the 
neutral score. Scores below 0 reflect a negative influ-
ence of the item on quality of life, and those above 
0 reflect positive influences. The impact scores are 
weighted (impact rating x importance rating), so the 
actual scores per item can range from −9 to 9 [27].
Cost‑effectiveness
Data on health care resources use during the whole study 
period will be extracted from electronic medical records 
from the general practitioners and for health status the 
EQ  5D questionnaire will be used at baseline and after 
2.5 years follow-up.
Sample size
In our previous study, the self-management intervention 
BGI achieved a significant BMI reduction of 0.77 after 
9 months in screen-detected T2DM patients (BMI −0.39 
in the intervention group vs. +0.38 in the control group) 
[2]. For the current study a minimum sample size of 88 
(44 per group) is required to achieve 80% power to detect 
a difference of 0.77 in a design with 6 repeated measure-
ments of BMI (weight is measured every three months as 
part of usual diabetes care) having a AR (1) covariance 
structure when the standard deviation is 1.7, the correla-
tion between subsequent observations on the same sub-
ject is 0.70, and alpha 0.05. With an expected drop-out 
rate of 20%, we need to include a total of 106 patients.
Statistical analyses
The efficacy analysis will be performed by intention-to-
treat analysis, including all patients from whom a fol-
low-up assessment is available. If necessary a multiple 
imputation technique will be used for missing data. The 
primary outcome will be analysed by using Generalized 
Estimated Equations (GEE) for repeated measures, with 
baseline BMI as covariate and time, intervention and the 
interaction of time and intervention as fixed variables. 
The secondary outcomes will be analysed with ANCOVA 
on the change from baseline to follow-up. In addition dif-
ferences in characteristics (e.g. age, sex, education level) 
of participants and non-participants will be evaluated.
Cost‑effectiveness
Lifetime costs and health effects (based on the EQ  5D) 
will be estimated using a modified probabilistic diabetes 
model. This validated model has been used before and is 
described in more detail elsewhere [28–30]. In brief, the 
model simulates the natural history of type 2 diabetes and 
calculates costs and quality-adjusted life years (QALYs) 
for Dutch T2DM patients [30]. The model includes a 
health state for cardiovascular disease (CVD; myocardial 
infarction, stroke, peripheral arterial disease), microvas-
cular complications (end-stage renal disease, retinopa-
thy and neuropathy), uncomplicated type 2 diabetes and 
death. The model computes the occurrence of the above-
mentioned diabetes-related complications and the excess 
mortality due to diabetes. Based on the estimated events 
and prevalence of complications, it computes diabetes-
related lifetime medical costs and QALYs.
To calculate lifetime costs and outcomes, each health 
state is assigned a value in terms of medical costs and 
utility (health-related quality of life), and this value is 
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multiplied by the prevalence of the health states over 
time.
In addition to the model input data described above, 
medication costs of glucose-lowering drugs, anti-hyper-
tensive medication and cholesterol-lowering drugs used 
during the total follow-up period will be included in the 
cost calculation. Costs of the BGI-course and total health 
care resources (including consultations of the dietician) 
use during the whole study period will also be included 
in the cost calculation. These costs will be extrapolated 
to estimate lifetime medication costs, assuming that the 
cost difference between the BGI-group and the control-
group remains constant over time.
The model will calculate two lifetime health outcomes 
(life years, QALYs) and costs for each patients (dis-
counted and undiscounted). To correct for confounding 
and improve model estimates of the difference in out-
come between the BGI-group and the control-group, the 
following baseline covariates will be used: age, sex, dura-
tion of diabetes, history of cardiovascular disease, smok-
ing, HbA1c, systolic blood pressure, total cholesterol and 
HDL cholesterol.
The primary outcome of the cost-effectiveness analy-
ses will be the cost-effectiveness of BGI versus control, 
expressed as the incremental cost-effectiveness ratio 
(ICER), calculated by dividing the incremental costs 
by the incremental QALYs or incremental life years. 
Uncertainty surrounding the cost-effectiveness ratios as 
calculated from the model will be expressed using a cost-
effectiveness plane. A cost-effectiveness acceptability 
curve will be created to determine whether implemen-
tation of BGI is cost-effective given different thresholds 
of willingness to pay for a QALY (e.g. a threshold of € 
20.000 per QALY).
Discussion
In diabetes self-management education the ‘one-size-fits-
all’ approach is not very effective. Not all patients will 
possess the necessary self-management skills. While a 
certain motivation and perseverance may be needed to 
change one’s behaviours, successful maintenance ulti-
mately depends on one’s ability to anticipate and deal 
with a wide range of potential stressors that challenge 
diabetes management and long-term health. This is the 
central tenet of proactive coping, a self-regulatory model 
which describes the steps people take in pursuit of their 
long-term goals. From our previous research we know 
that proactive coping may be a better predictor of good 
long-term self-management than either intentions or 
self-efficacy [18]. The current study will add knowledge 
about the program in three different aspects: its 2.5 year 
(cost-) effectiveness and the impact of pre-selection of 
patients. This knowledge will be of importance, because 
to deal with the global diabetes epidemic, cost-effective 
self-management education programs that are also effec-
tive on the long run are needed.
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